Mizuho analyst Anthony Petrone lowered the firm’s price target on MannKind (MNKD) to $7 from $8 and keeps an Outperform rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- MannKind price target raised to $10 from $8 at H.C. Wainwright
- MannKind price target raised to $10 from $8 at Wells Fargo
- MannKind reports Q1 EPS (2c), consensus 1c
- MannKind Buy Rating Reiterated as United Therapeutics Expands DPI Partnership; $8 Price Target Unchanged
- MNKD Earnings this Week: How Will it Perform?